ArriVent Biopharma, Inc. filed its quarterly report with the SEC on November 9, 2026, covering the fiscal period ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of November 5, 2026, ArriVent Biopharma reported 51,723,074 shares of common stock outstanding.
  • Listing: The company's common stock, $0.0001 par value per share, trades under the symbol AVBP on The Nasdaq Global Market, according to the filing.
  • Emerging growth company: The registrant indicated it qualifies as an emerging growth company under Rule 12b-2 of the Exchange Act and has not elected to use the extended transition period for new accounting standards.
  • Filer classification: ArriVent Biopharma is classified as a non-accelerated filer and a smaller reporting company status box was left unchecked, with the emerging growth company box marked.
  • Commission file number: The filing carries commission file number 001-41929.
  • Principal offices: The company is headquartered at 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073, as stated in the filing.

ArriVent Biopharma's September 30, 2026 Quarterly Disclosure Details

ArriVent Biopharma, Inc. (NASDAQ:AVBP), a Delaware-incorporated biopharmaceutical company focused on developing product candidates through preclinical studies and clinical trials, filed its quarterly report for the period ended September 30, 2026 with the Securities and Exchange Commission on November 9, 2026. The company disclosed that its common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Global Market under the ticker AVBP. As of November 5, 2026, the registrant reported 51,723,074 shares of common stock outstanding.

According to the filing, ArriVent Biopharma's quarterly report includes condensed financial statements, condensed balance sheets, condensed statements of operations and comprehensive loss, condensed statements of stockholders' equity or deficit, and condensed statements of cash flows, all of which are unaudited. The company also noted it is subject to various forward-looking risks, including those related to the timing and progress of clinical trials, regulatory filings and approvals, capital requirements, and the potential impact of tariffs and economic policy changes on its operations. The filing states that these forward-looking statements involve known and unknown risks and uncertainties that are in some cases beyond the company's control.

The registrant confirmed it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and that it has submitted all required Interactive Data Files electronically. The company is incorporated in Delaware and carries I.R.S. Employer Identification Number 86-3336099.

What Was Disclosed

ArriVent Biopharma filed its quarterly report for the period ended September 30, 2026, disclosing 51,723,074 shares outstanding as of November 5, 2026, its Nasdaq listing under AVBP, its emerging growth company status, and its principal offices in Newtown Square, Pennsylvania.